Upstream Bio (UPB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Upstream Bio (UPB) is Moderate Underperform.

The composite score behind that read is -0.39, weighing +0.61 of bullish evidence against -0.41 bearish.

Upstream Bio last closed at $4.59, -5.36% on the session.

Against the IVW growth benchmark the position is -5.97% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

17 graded predictions for UPB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Upstream Bio in the 18th percentile on return on equity, where 100 is best.

Upstream Bio is classified under Health Care / Biotechnology, with a market capitalisation of $265.64M.

StockMap tracks Upstream Bio as the 218th largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite Upstream Bio ranks 329th of 365 in the group, against a group median of -0.21.